{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T06:32:14Z","timestamp":1786516334083,"version":"build-2736575974"},"reference-count":20,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dan Med J"],"abstract":"<jats:p>INTRODUCTION. Patients with cardiovascular and chronic kidney disease (CKD) are at increased risk of adverse outcomes, calling for early monitoring of kidney function to reduce morbidity and mortality. We aimed to estimate CKD prevalence, albuminuria, kidney monitoring practices and adherence to guideline-recommended treatment in cardiology outpatients.\n\nMETHODS. This cross-sectional study included 196 patients from a cardiology outpatient clinic in Svendborg, Denmark. Blood and urine samples were analysed for the estimated glomerular filtration rate (eGFR), urine albumin-to-creatinine ratio and secondary markers of kidney impairment, in accordance with international guidelines. Medical history, risk factors and demographic information were obtained from a questionnaire. Regular CKD monitoring (\u2265 1 \u00d7\/year) and nephroprotective drug use were evaluated.\n\nRESULTS. The prevalence of CKD was 50.5%, and 20.9% of patients were categorised with a high or very high CKD risk. In patients with CKD, 23.2% had albuminuria despite normal eGFR, 22.2% had secondary markers of kidney impairment, and only 15.2% were aware of having reduced kidney function. Regular kidney monitoring was lacking in 33.7% of patients, and 64.3% of patients with CKD did not receive the recommended treatment.\n\nCONCLUSIONS. The prevalence of CKD was high in cardiology outpatients. Limited awareness of kidney function, in combination with infrequent screening of CKD, led to inadequate prescription of nephroprotective drugs.\n\nFUNDING. Funded by the Cardiovascular Research Unit, Odense University Hospital Svendborg.\n\nTRIAL REGISTRATION. Not relevant.<\/jats:p>","DOI":"10.61409\/a08250635","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T05:52:26Z","timestamp":1778133146000},"page":"1-9","source":"Crossref","is-referenced-by-count":0,"title":["The prevalence and treatment of chronic kidney disease in a cardiology outpatient clinic"],"prefix":"10.61409","author":[{"given":"Eline","family":"Panadevo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Thye-R\u00f8nn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrine","family":"Schultz Overgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Egstrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jess","family":"Lambrechtsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Auscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"40208","published-online":{"date-parts":[[2026,4]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Ene-Iordache B, Perico N, Bikbov B, et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. Lancet Glob Health. 2016;4(5):e307-e319. https:\/\/doi.org\/10.1016\/S2214-109X(16)00071-1","DOI":"10.1016\/S2214-109X(16)00071-1"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Wagner M, Wanner C, Kotseva K, et al. Prevalence of chronic kidney disease and its determinants in coronary heart disease patients in 24 European countries: insights from the EUROASPIRE IV survey of the European Society of Cardiology. Eur J Prev Cardiol. 2017;24(11):1168-1180. https:\/\/doi.org\/10.1177\/2047487317708891","DOI":"10.1177\/2047487317708891"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-1305. https:\/\/doi.org\/10.1056\/NEJMoa041031","DOI":"10.1056\/NEJMoa041031"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Nguyen NTQ, Cockwell P, Maxwell AP, et al. Chronic kidney disease, health-related quality of life and their associated economic burden among a nationally representative sample of community dwelling adults in England. PLoS One. 2018;13(11):e0207960. https:\/\/doi.org\/10.1371\/journal.pone.0207960","DOI":"10.1371\/journal.pone.0207960"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S): S117-S314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"ref5","unstructured":"National Guideline Centre (UK). Chronic heart failure in adults: diagnosis and management. London: National Institute for Health and Care Excellence (NICE), 2018"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Lindhardt M, Knudsen ST, Saxild T, et al. Treating chronic kidney disease in Danish primary care: results from the observational ATLAS study. BMC Prim Care. 2025;26(1):23. https:\/\/doi.org\/10.1186\/s12875-025-02721-4","DOI":"10.1186\/s12875-025-02721-4"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Mannheimer E, J\u00f8rgensen MB, Hommel K, et al. Management and treatment of chronic kidney disease in the Danish Lolland-Falster Health Study: focus on renoprotection and cardiovascular disease prevention. Clin Kidney J. 2025;18(9):sfaf242. https:\/\/doi.org\/10.1093\/ckj\/sfaf242","DOI":"10.1093\/ckj\/sfaf242"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436-1446. https:\/\/doi.org\/10.1056\/NEJMoa2024816","DOI":"10.1056\/NEJMoa2024816"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424. https:\/\/doi.org\/10.1056\/NEJMoa2022190","DOI":"10.1056\/NEJMoa2022190"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474-484. https:\/\/doi.org\/10.1093\/eurheartj\/ehab777","DOI":"10.1093\/eurheartj\/ehab777"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109-121. https:\/\/doi.org\/10.1056\/NEJMoa2403347","DOI":"10.1056\/NEJMoa2403347"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"McClellan WM, Newsome BB, McClure LA, et al. Chronic kidney disease is often unrecognized among patients with coronary heart disease: the REGARDS Cohort Study. Am J Nephrol. 2009;29(1):10-17. https:\/\/doi.org\/10.1159\/000148645","DOI":"10.1159\/000148645"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Amen\u00f3s AC, Gonz\u00e1lez-Juanatey JR, Guti\u00e9rrez PC, et al. Prevalence of chronic kidney disease in patients with or at a high risk of cardiovascular disease. Rev Esp Cardiol. 2010;63(2):225-228. https:\/\/doi.org\/10.1016\/S1885-5857(10)70041-4","DOI":"10.1016\/S1885-5857(10)70041-4"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Kampmann JD, Heaf JG, Mogensen CB, et al. Prevalence and incidence of chronic kidney disease stage 3-5: results from KidDiCo. BMC Nephrol. 2023;24(1):17. https:\/\/doi.org\/10.1186\/s12882-023-03056-x","DOI":"10.1186\/s12882-023-03056-x"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Savarese G, Settergren C, Schrage B, et al. Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: a blueprint for clinical trial design. Int J Cardiol. 2020;313:76-82. https:\/\/doi.org\/10.1016\/j.ijcard.2020.04.068","DOI":"10.1016\/j.ijcard.2020.04.068"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Shlipak MG, Tummalapalli SL, Boulware LE, et al. The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2021;99(1):34-47. https:\/\/doi.org\/10.1016\/j.kint.2020.10.012","DOI":"10.1016\/j.kint.2020.10.012"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Fried L, Schmedt N, Folkerts K, et al. High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database. Nephrol Dial Transplant. 2023;38(3):630-643. https:\/\/doi.org\/10.1093\/ndt\/gfac140","DOI":"10.1093\/ndt\/gfac140"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Gaede P, Vedel P, Parving HH, et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet. 1999;353(9153):617-622. https:\/\/doi.org\/10.1016\/S0140-6736(98)07368-1","DOI":"10.1016\/S0140-6736(98)07368-1"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Oellgaard J, G\u00e6de P, Rossing P, et al. Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study. Diabetologia. 2018;61(8):1724-1733. https:\/\/doi.org\/10.1007\/s00125-018-4642-y","DOI":"10.1007\/s00125-018-4642-y"}],"container-title":["Danish Medical Journal"],"original-title":[],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T06:02:51Z","timestamp":1786514571000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/dmj\/A08250635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":20,"URL":"https:\/\/doi.org\/10.61409\/a08250635","relation":{},"ISSN":["2245-1919"],"issn-type":[{"value":"2245-1919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}